Galimedix therapeutics initiates pivotal phase 2 study with gal-101 eye drops in dry amd

Kensington, md., dec. 23, 2024 (globe newswire) -- galimedix therapeutics, inc. (“galimedix”), a phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced the initiation of a phase 2 study (edream; nct06659549 ) with gal-101 eye drops in patients with dry age-related macular degeneration (dry amd), a leading cause of adult blindness. the randomized, double-blind, placebo-controlled multicenter study will evaluate the efficacy and safety of gal-101 eye drops in patients with geographic atrophy, an advanced form of dry amd.
AMD Ratings Summary
AMD Quant Ranking